Cardiome Pharma Corp. (USA) (CRME)

pops83 (30.62) Submitted: 4/02/08 2:22 AM : Start Price: $8.34 CRME Score: -15.97

Vernakalant hydrochloride (KYNAPID) is the first new drug for use in conversion of Afib in 8 years. With a conversion time of +/- 11 minutes, I can see this being the first line I.V. drug used for new onset Afib patients in the ER setting. While there are other drugs currently available to treat Afib, they have their fair share of potential complications which are on par with, if not worse then what the study results for KYNAPID have shown, yet do not have the rapidness of response time that KYNAPID has shown. About the only other form of therapy with a faster response time is to cardiovert, (Plug your butt into a wall socket and hit the switch. FUN, FAST and it HURTS!!!!!)





I feel that this will be rapidly accepted as the gold standard treatment for ER patient dx'd with new onset Afib. After all, you will only want to get lit up like a christmas tree one time to know that you would greatly prefer an alternative that won't hurt as much.





When the oral version reaches market, which will open the patient population base exponentially, the sky could very well be the limit.





So, I say a year or so on the I.V. form of this drug.


Long term hold based on the oral version still being in phase 2.





As to this being a one drug wonder company, what a wonderful drug it is. The returns from the I.V. form alone in MHO will generate revenues that should finance research into other drugs for many years to come, or they get bought out for a nice premium. Who knows?





I'm buyin all I can get before the FDA finally gets their act together on their PDUFA mess/delays.... If I am wrong, y'all will hear the blood curdling scream for miles ! LOL





Fool on





POPS83

Report this Post Replies: 0 | Reply | Permalink